Your session is about to expire
← Back to Search
Cabozantinib + Cetuximab for Head and Neck Cancer
Study Summary
This trial is testing the safety of cabozantinib combined with cetuximab to treat HNSCC.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 45 Patients • NCT02101736Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I understand the study requirements and have signed the consent form.I am 18 years old or older.I have received more than 70 Gy of radiation to my neck or head in the last 2 months.I have recently had specific cancer treatments.I am currently taking blood thinners.My tumor is growing into or around major blood vessels.My brain metastases are treated and stable.I have not had major surgery recently.I have symptoms of an underactive thyroid.I have received chemotherapy for cancer that has spread.I need ongoing treatment with strong CYP3A4 inducers.I have recovered from side effects of previous treatments, with only mild symptoms remaining.My blood tests and organ functions are within normal ranges.I am not pregnant and can become pregnant.My liver function is significantly impaired.I am fully active or can carry out light work.I have had serious bleeding issues recently.I do not have any severe, uncontrolled illnesses.All my cancer sites were checked within the last 28 days.I have a serious wound, ulcer, or bone fracture that isn't healing.I have not had radiation therapy recently.My cancer has spread or returned and cannot be removed by surgery.I have been treated with cabozantinib before.I have had cancer other than my current one in the last 5 years, with some exceptions.My cancer is a type of squamous cell carcinoma located in the head or neck.I cannot swallow whole pills.My tumor has spread to my gastrointestinal tract or airways recently.
- Group 1: Cabozantinib in Combination With Cetuximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned Cabozantinib for medical use?
"Cabozantinib's safety has been evaluated to the extent that it received a score of 1 on a scale from 1 to 3. This is because this phase one trial only provides limited evidence for its efficacy and security."
In how many distinct locations is this clinical trial taking place?
"Nine sites are presently participating in this clinical trial, including Memorial Sloan Kettering Monmouth (Middletown), Lehigh Valley Health Network (Allentown) and Memorial Sloan Kettering Westchester (Harrison). Several other medical centres have joined the study as well."
How often has Cabozantinib been utilized in past experiments?
"Currently, there are 229 active clinical trials that focus on Cabozantinib with 41 of them being in the final phase. Most tests take place in Dresden, Arizona; however a total of 12373 sites worldwide provide testing for this drug."
How many participants are undergoing treatment as part of this clinical experiment?
"This trial requires 24 eligible patients to participate, with recruitment taking place at sites such as Memorial Sloan Kettering Monmouth in Middletown, Pennsylvania and Lehigh Valley Health Network in Allentown, New york."
What does Cabozantinib generally aim to treat?
"Patients who have already undergone anti-vegf treatment, present with metastatic squamous cell carcinoma of the head and neck (hnscc), or are deemed at a higher risk for developing cancer can benefit from Cabozantinib."
Is enrollment currently open for this trial?
"Clinicaltrials.gov reveals that the trial is actively recruiting patients, with its initial posting on September 7th 2018 and most recent update being October 14th 2022."
Share this study with friends
Copy Link
Messenger